<DOC>
	<DOCNO>NCT00165594</DOCNO>
	<brief_summary>Phase I study : To investigate primary objective ( maximal tolerate dose dose-limiting toxicity ) secondary objective ( pharmacokinetics , safety , estimation recommend dose , anti-tumor effect evaluable case ) E7070 patient gastric cancer extensive intermediate metabolizer type ( EM/IM ) CYP2C9 CYP2C9 intravenously administer every 3 week . Phase IIa study : To investigate primary objective ( response rate efficacy assessment ) secondary objective ( frequency severity adverse drug reaction , pharmacokinetics ) E7070 patient gastric cancer EM/IM type intravenously administer every 3 week .</brief_summary>
	<brief_title>A Study E7070 Patients With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Inclusion Criteria ( Phase I ) : Patients histologically cytologically confirm gastric cancer . Patients nonresponder exist treatment prove efficacy gastric cancer , effect longer expect exist treatment . Patients age ≥20 year &lt; 75 year time registration . Patients grade 0 2 Eastern Cooperative Oncology Group ( ECOG ) Performance status ( PS ) Patients hospitalize begin study treatment end first cycle . Patients wellmaintained function major organ ( bone marrow , liver , kidney , lung ) . 1 . WBCl count : ≥3,000/mm3 , ≤12,000/mm3 2 . Neutrophil count : ≥2,000/mm3 3 . Platelet count : ≥100,000/mm3 4 . Hemoglobin : ≥9.0 g/dL 5 . Aspartate aminotransferase ( AST ) : ≤2.5 time upper limit normal range study site 6 . Alanine aminotransferase ( ALT ) : ≤2.5 time upper limit normal range study site 7 . Total bilirubin : ≤1.5 time upper limit normal rage study site 8 . Serum creatinine : ≤1.5 time upper limit normal range study site 9 . Partial pressure oxygen arterial blood : ≥65 torr Patients EM/IM regard CYP2C9 CYP2C19 Patients consent participate study write consent form Patients carryover adverse drug reaction ( ) affect evaluation previous treatment safety E7070 completion previous treatment . Required period washout end previous treatment begin study treatment follow : 1 . Chemotherapy , endocrinotherapy , immunotherapy , radiotherapy , surgical therapy , investigational product : 4 week 2 . Nitrosourea agent mitomycin C : 6 week 3 . Blood transfusion , blood preparation , hematopoietic preparation include GCSF preparation : 2 week Patients expect survive least 3 month begin study treatment . Exclusion Criteria ( Phase I ) : Patients systemic infectious disease . Patients large volume pleural effusion , ascites , pericardial effusion require drainage . Patients brain metastasis clinical symptom . Patients clinically significant mental disorder , attack , central nervousrelated disorder . Patients meet follow serious complication : 1 . Ischemic heart disorder heart diseases include arrhythmia require medical treatment ( exclude leave ventricular hypertrophy , mild leave ventricular load , mild right bundle branch block accompany hypertension ) . 2 . Myocardial infarction within 6 month . 3 . Hepatic cirrhosis . 4 . Interstitial pneumonia pulmonary fibrosis . 5 . Gastrointestinal fresh hemorrhage require repeat blood transfusion . 6 . Uncontrolled diabetes mellitus ( hemoglobin Alc ( HBAlc ) : ≥8.0 % ) Patients whose NYHA classification II IV . Patients meet follow item regard prolonged QT/QTc interval : 1 . A history prolong QT/QTc interval ( male : QTc &gt; 450 m , female : QTc &gt; 470 m ( Bazett 's correction ) ) 2 . At time registration : QTc &gt; 500 m ( Bazett 's correction ) 3 . A history serious arrhythmia include Torsades de point Patients require nutrition support use intravenous hyper alimentation ( IVH ) enteral nutrition . Patients history hypersensitivity sulfonamide . Premenopausal woman currently pregnant , breastfeed , childbearing potential . Premenopausal woman childbearing potential defined woman le 12month elapse last menstruation , pregnant test positive perform time registration , consent use appropriate contraceptive method . Male patient intention contraception . Patients coumarin agent take within 2 week start study treatment . Patients currently take agent know cause prolong QT/QTc interval . Patients positive test human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis B virus surface antigen ( HBs antigen ) . Patients history drug alcohol abuse . Patients continuously require systemic treatment steroid study period . Patients presently participate another clinical study . Patients judge ineligible participate study investigator sub investigator . Inclusion Criteria ( Phase IIa ) : Patients histologically cytologically proved efficacy gastric cancer . Patients unable undergo resection recurrence cancer . Patients evaluable lesion base RECIST . Patients treat 1 2 regimen previous chemotherapy gastric cancer ( least 1 regimen use fluorouracil agent ) . Adjuvant chemotherapy oral pyrimidine fluoride agent include number previous regimen . Patients age ≥20 year &lt; 70 year . Patients grade 0 2 Eastern Cooperative Oncology Group ( ECOG ) Performance status ( PS ) Patients hospitalize begin study treatment end first cycle . Patients wellmaintained function major organ ( bone marrow , liver , kidney , lung ) . 1 . WBC count : ≥3,000/mm3 , ≤12,000/mm3 2 . Neutrophil count : ≥ 2,000/mm3 3 . Platelet count : ≥100,000/mm3 4 . Hemoglobin : ≥9.0 g/dL 5 . Aspartate aminotransferase [ AST ] : ≤2.5 time upper limit normal center 6 . Alanine aminotransferase [ ALT ] : ≤2.5 time upper limit normal center 7 . Total bilirubin : ≤1.5 time upper limit normal center 8 . Serum creatinine : ≤1.5 time upper limit normal center 9 . Partial pressure oxygen arterial blood : ≥65 torr Patients EM/IM regard CYP2C9 CYP2C19 Patients consent participate study write consent form . Patients carryover adverse drug reaction ( ) affect evaluation previous treatment safety E7070 completion previous treatment . Required period washout end previous treatment begin study treatment follow . 1 . Chemotherapy , endocrinotherapy , immunotherapy , radiotherapy , surgical therapy , investigational product : ≥4 week 2 . Nitrosourea agent mitomycin C : ≥6 week 3 . Blood transfusion , blood preparation , hematopoietic preparation include GCSF preparation : ≥2 week Patients expect survive least 3 month begin treatment investigational product . Exclusion Criteria ( Phase IIa ) : Patients systemic infectious disease . Patients severe peritoneal dissemination meet follow item . 1 . Clinical sign ileus sub ileus 2 . Worse moderate ascites ( beyond pelvic cavity ) 3 . Clear peritoneal dissemination confirm enema Patients large volume pleural effusion , ascites , pericardial effusion require drainage . Patients brain metastasis clinical symptom Patients clinically significant metal disorder , attack , central nervousrelated disorder . Patients meet follow serious complication : 1 . Ischemic heart disease heart disease include arrhythmia require medical treatment ( exclude leave ventricular hypertrophy , mild leave ventricular load , mild right bundle branch block accompany hypertension ) 2 . Myocardial infarction within 6 month 3 . Hepatic cirrhosis 4 . Interstitial pneumonia pulmonary fibrosis 5 . Gastrointestinal fresh hemorrhage require repeat blood transfusion 6 . Uncontrolled diabetes mellitus ( hemoglobin Alc ( HbAlc ) ≥ 8.0 % ) Patients whose NYHA classification II IV . Patients meet follow item regard prolonged QT/QTc interval . 1 . A history prolong QT/QTc interval ( male : QTc &gt; 450 m , female : QTc &gt; 470 m ( Bazett 's correction ) ) 2 . At time registration : QTc &gt; 500 m ( Bazett 's correction ) 3 . A history serious arrhythmia include Torsades de point Patients require nutrition support intravenous hyper alimentation ( IVH ) enteral nutrition . Patients history hypersensitivity sulfonamide . Patients active multiple malignant tumor ( include diseasefree interval within 5 year ) Premenopausal woman currently pregnant , breastfeed childbearing potential . Premenopausal woman childbearing potential defined woman le 12month elapse last menstruation pregnant test positive perform time registration , consent appropriate contraceptive method . Male patient intention contraception . Patients currently take coumarin agent take within 2 week begin study treatment . Patients currently take agent know cause prolong QT/QTc interval . Patients positive test human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis B virus surface antigen ( HBs antigen ) . Patients history drug alcohol abuse Patients continuously require systemic treatment steroid study period . Patients presently participate another clinical study . Patients judge ineligible participate clinical study investigator sub investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>Phase I</keyword>
	<keyword>Phase IIa</keyword>
	<keyword>E7070</keyword>
	<keyword>Indisulam</keyword>
	<keyword>Pharmacogenomic</keyword>
	<keyword>2C19</keyword>
</DOC>